Abstract
A clinical trial with HDM as consolidation therapy in ALL was started in June 1975. Ten departments of pediatrics treating almost all cases of childhood leukemia in Norway are now participating. Three courses of HDM, 500 mg/sq.m. at 3-weekly intervals, have been used in 59 children with ALL and one with AML. One child in incomplete remission died following HDM and there were nine other cases of marked or severe reactions, following a total of 154 courses in 60 patients including 5 cases of allergic-toxic skin reactions.
Thirty-eight of forty patients in primary complete remission have been in sustained remission for 3-22 months, only two of the 40 cases have so far relapsed.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moe, P. HIGH DOSE METHOTREXATE (HDM) IN ACUTE LYMPHOCYTIC LEUKEMIA IN CHILDHOOD. Pediatr Res 12, 69 (1978). https://doi.org/10.1203/00006450-197801000-00054
Issue Date:
DOI: https://doi.org/10.1203/00006450-197801000-00054
This article is cited by
-
Vector magnetic field measurements and penumbral structure
Solar Physics (1991)